GlassScriptPhysician profile
Jacob Gise
NPI 1700437753
$9,460.05
in general payments reported to CMS, 2019-2025
41 companies · $1,812 in 2025
The $1,812 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,263 · 2022: $1,312 · 2023: $1,572 · 2024: $1,502 · 2025: $1,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,885.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,396.05 | 2021 | |
| Abbvie INC. | $1,214.11 | 2021-2025 | |
| Novo Nordisk INC | $884.20 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $518.79 | 2021-2025 | |
| Lilly USA, LLC | $501.84 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $463.28 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $410.38 | 2022-2025 | Rexulti |
| Amgen INC. | $367.96 | 2021-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $367.46 | 2021-2025 | |
| Glaxosmithkline, LLC. | $352.61 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corcept Therapeutics | $314.45 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $291.12 | 2021-2025 | Veozah |
| Merck Sharp & Dohme LLC | $224.76 | 2021-2024 | Steglatro, Belsomra, Steglujan |
| Takeda Pharmaceuticals U.S.A., INC. | $199.26 | 2021-2024 | Trintellix |
| Amarin Pharma, INC. | $197.79 | 2021-2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $171.81 | 2021-2023 | Xarelto |
| Dexcom, INC. | $158.49 | 2021-2024 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $155.85 | 2023-2024 | Qelbree, Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $142.47 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.06 | 2021-2024 | Jardiance |
| Eisai INC. | $103.55 | 2021 | |
| Corium, LLC | $97.39 | 2022-2025 | Azstarys, Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $94.81 | 2022-2025 | |
| Exact Sciences Corporation | $91.61 | 2024-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $87.33 | 2024-2025 | Zoryve, Livalo |
| Phathom Pharmaceuticals, INC. | $83.33 | 2023-2025 | Voquezna |
| Lundbeck LLC | $62.69 | 2024-2025 | Rexulti |
| Medtronic, INC. | $52.51 | 2021-2024 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $35.01 | 2023-2025 | Auvelity |
| Abiomed | $32.83 | 2025 | |
| Si-Bone, INC. | $32.76 | 2021 | |
| Neos Therapeutics, LP | $31.98 | 2021 | |
| Currax Pharmaceuticals LLC | $30.86 | 2021 | |
| Arbor Pharmaceuticals, INC. | $28.47 | 2021 | |
| Nalu Medical, INC. | $27.57 | 2023 | Nalu Neurostimulation System |
| Alexion Pharmaceuticals, INC. | $21.88 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $19.24 | 2023 | Prehevbrio |
| Madrigal Pharmaceuticals | $19.20 | 2025 | Rezdiffra |
| Inspire Medical Systems, INC. | $19.13 | 2023 | Inspire |
| Sanofi Pasteur INC. | $16.46 | 2022 | |
| Intuity Medical INC | $12.70 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Gise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.